Pasireotide Impurities

Pasireotide, sold under the brand name Signifor, is an orphan drug approved in the United States and the European Union for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a synthetic cyclic peptide somatostatin analogue with high binding affinity for multiple somatostatin receptor subtypes, notably somatostatin receptor type 5, and it reduces adrenocorticotropic hormone secretion from pituitary corticotroph adenomas. The molecule is available as an immediate release subcutaneous formulation and as a long acting intramuscular depot formulation for extended exposure. From a pharmaceutical perspective pasireotide requires peptide-specific manufacturing controls including careful oxidation and deamidation management, validated peptide mapping and mass spectrometry characterization, and aseptic sterile processing for the parenteral products. Clinically relevant pharmacology includes inhibition of hormone secretion through G protein coupled receptor signaling and measurable effects on glucose regulation that reflect reduced insulin and incretin release.